Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00927589 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1 study of Solid Cancers, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
- 20
- Study locations
NCT00927589 is a Phase 1 study of Solid Cancers that has completed, run by Genentech. The registered enrollment target is 59 participants. The trial reports 20 study locations across 10 states.
The verdict
NCT00927589, a Phase 1 study of Solid Cancers, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase Ib, multicenter, single-arm, open-label study is designed to evaluate the effect of trastuzumab on QTcF interval and to characterize the effects of trastuzumab on carboplatin pharmacokinetics in patients with HER2-positive metastatic or locally advanced inoperable cancer. The QT interval is a measure of time between the start of the Q wave and the end of the T wave in the heart's electrical cycle. The QTcF interval is the QT interval as calculated using Fridericia's correction; the QTcB interval is the QT interval as calculated using Bazett's correction.
Conditions Studied
Interventions
- DRUG carboplatin
- DRUG docetaxel
- DRUG trastuzumab
Study Locations (20)
Texas
- - Dallas
- - Galveston
- - Houston
- - Houston
- - San Antonio
- - Temple
California
- - Beverly Hills
- - La Jolla
- - San Diego
- - Santa Rosa
- - Whittier
Tennessee
- - Memphis
- - Nashville
Arizona
- - Scottsdale
Florida
- - Miami
Kansas
- - Wichita
Montana
- - Billings
New Mexico
- - Farmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2009-07 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00927589
The ClinicalTrials.gov registry entry for NCT00927589 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Cancers appearing as the primary indexed condition, and to 3 interventions - of which carboplatin is the first listed.
NCT00927589 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Texas, California, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00927589 about?
NCT00927589 is a clinical study titled "A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer". This Phase Ib, multicenter, single-arm, open-label study is designed to evaluate the effect of trastuzumab on QTcF interval and to characterize the effects of trastuzumab on carboplatin pharmacokinetics in patients with HER2-positive metastatic or locally advanced inoperable cancer. The QT interval...
What is the current status of trial NCT00927589?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2009-07. Estimated completion is 2013-02.
What conditions does trial NCT00927589 study?
This clinical trial studies the following conditions: Solid Cancers.
What interventions are being tested in trial NCT00927589?
The interventions under investigation include: carboplatin (DRUG), docetaxel (DRUG), trastuzumab (DRUG).
Who is sponsoring clinical trial NCT00927589?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00927589 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Kansas, Montana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Cancers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.